indazoles has been researched along with Sarcoma in 126 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (0.79) | 29.6817 |
| 2010's | 89 (70.63) | 24.3611 |
| 2020's | 36 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Bovee, JVMG; Fiocco, M; Gelderblom, H; Haas, RL; Hayes, AJ; Koenen, AM; Krol, S; Miah, AB; Schrage, Y; Steeghs, N; Thway, K; van Coevorden, F; van Houdt, W; van Meekeren, M; Zaidi, S | 1 |
| Ata, S; Cil, T; Duman, BB; Haksoyler, V; Koseci, T; Nayir, E; Olgun, P | 1 |
| Ahrens, M; Andresen, C; Apostolidis, L; Aybey, B; Bauer, S; Beck, K; Bitzer, M; Boerries, M; Brandts, CH; Brors, B; Egerer, G; Folprecht, G; Fröhling, S; Glimm, H; Hamacher, R; Heilig, CE; Heining, C; Hohenberger, P; Horak, P; Hübschmann, D; Illert, AL; Jost, PJ; Keilholz, U; Kindler, T; Klauschen, F; Köhler, BC; Kreutzfeldt, S; Laßmann, A; Lipka, DB; Mechtersheimer, G; Mock, A; Möhrmann, L; Mughal, SS; Pirmann, S; Renner, M; Richter, D; Richter, S; Schlenk, RF; Schröck, E; Schulze-Osthoff, K; Siveke, JT; Stenzinger, A; Teleanu, V; von Bubnoff, N; Weichert, W; Westphalen, CB; Winter, U | 1 |
| Baek, W; Cho, HJ; Choi, YL; Hong, JY; Kim, HS; Kim, SH; Kim, SK; Kwon, M; Lee, J; Lee, Y; Lee, YH; Yun, KH | 1 |
| Bauer, S; Chemnitz, JM; Crysandt, M; Egerer, G; Grünwald, V; Hamacher, R; Hentschel, L; Ivanyi, P; Kasper, B; Kopp, HG; Kunitz, A; Lindner, L; Liu, X; Richter, S; Schöffski, P; Schuler, MK; Steffen, B; Stein, A | 1 |
| Aoyama, T; Azuma, K; Furutani, R; Hama, T; Hashimoto, K; Hiraide, M; Ito, K; Kobayashi, K; Nakano, K; Okawa, T; Sato, H; Sugiyama, E; Suzuki, K; Tajima, M; Takahashi, S; Tomomatsu, J; Yuasa, T | 1 |
| Acar, R; Akgul, F; Artac, M; Aydin, SG; Bahceci, A; Besiroglu, M; Bilici, A; Cinkir, HY; Dal, P; Demir, H; Demiray, AG; Derin, S; Eraslan, E; Erdem, D; Ergun, Y; Erol, C; Goksu, SS; Guc, ZG; Gumusay, O; Gunaydin, UM; Kaplan, MA; Karaagac, M; Karaca, M; Koca, S; Koral, L; Menekse, S; Ocak, B; Ozkul, O; Ozveren, A; Ozyukseler, DT; Paydas, S; Sahin, S; Sakalar, T; Sakin, A; Seker, MM; Sunar, V; Turhal, S; Unal, OU; Yekeduz, E | 1 |
| Aglietta, M; Ahmad, Q; Bauer, S; Blay, JY; Cesne, AL; Demetri, GD; Dezzani, L; Gelderblom, H; Han, G; Hohenberger, P; Judson, I; Schöffski, P | 1 |
| Esser, M; Gast, GC; Horger, M; Kloth, C; Kraus, MS; Reinert, CP; Thaiss, WM | 1 |
| Adam, J; Assi, T; Baldi, GG; Barisella, M; Ben-Ami, E; Benjamin, RS; Blay, JY; Casali, PG; Czarnecka, AM; Desar, I; Duffaud, F; Dufresne, A; Fedenko, A; Ferraro, R; Frezza, AM; Gelderblom, H; Gounder, M; Gronchi, A; Hornick, JL; Jones, RL; Kawai, A; Le Cesne, A; Lo Vullo, S; Maki, RG; Mariani, L; Meurgey, A; Mir, O; Noguchi, E; Pantaleo, MA; Ravi, V; Sbaraglia, M; Schuetze, S; Siontis, B; Stacchiotti, S; Teterycz, P; Thornton, K; Vincenzi, B; Wagner, AJ; Yonemori, K | 1 |
| Eryılmaz, MK; Karaağaç, M | 1 |
| Belgioia, L; Bertulli, R; Buscaglia, M; Catalano, F; Comandini, D; Grassi, M; Rebuzzi, SE; Satragno, C | 1 |
| Elms, ML; Huang, PH; Jones, RL; Judson, I; Tan, AC; Wilding, CP | 1 |
| Bertucci, F; Blay, JY; Bompas, E; Brodowicz, T; Chaigneau, L; Chevreau, C; Decoupigny, E; Delcambre, C; Italiano, A; Laroche, L; Le Cesne, A; Le Deley, MC; Mir, O; Penel, N; Ray-Coquard, I; Saada-Bouzid, E; Salas, S; Taieb, S; Vanseymortier, M; Wallet, J | 1 |
| Araz, M; Artaç, M; Eryılmaz, MK; Kaplan, MA; Karaağaç, M; Sezgin, Y | 1 |
| Endo, M; Harabayashi, T; Hiraga, H; Nagamori, S; Sugawara, M; Takekuma, Y; Tanaka, H | 1 |
| Aydın, D; Beşiroğlu, M; Bilici, M; Dane, F; Doğu, GG; Hacıoğlu, B; Kaplan, NB; Karaca, M; Koca, S; Oruç, Z; Özçelik, M | 1 |
| Matsumine, A; Nakamura, T; Satonaka, H; Sudo, A; Tsujii, M | 1 |
| Huang, PH; Jones, RL; Loong, HH; Wilding, CP | 1 |
| Akaike, K; Hayashi, T; Ikegami, M; Kaneko, K; Kato, S; Kim, Y; Kohsaka, S; Kojima, S; Kurihara, T; Mano, H; Mizuno, S; Okubo, T; Saito, T; Sano, K; Sasa, K; Suehara, Y; Ueno, T; Yamaguchi, S | 1 |
| Ando, M; Goto, T; Hiraga, H; Kawai, A; Kobayashi, E; Kunisada, T; Matsumoto, Y; Naka, N; Nakayama, R; Nishida, Y; Okuma, T; Ozaki, T; Tsuchiya, H; Ueda, T; Urakawa, H | 1 |
| Levin, AS | 1 |
| Ahn, JH; Hong, JY; Kim, HS; Kim, JE; Kim, JH; Kim, TW; Lee, JS; Oh, CR | 1 |
| Agulnik, M; Attia, S; Eulo, V; Haarberg, S; Hirbe, AC; Kershner, T; Luo, J; Milhem, M; Monga, V; Moon, CI; Myles, S; Okuno, S; Parkes, A; Robinson, S; Seetharam, M; Toeniskoetter, J; Van Tine, BA | 1 |
| Bauer, S; Chemnitz, JM; Crysandt, M; Egerer, G; Grünwald, V; Ivanyi, P; Karch, A; Kasper, B; Kopp, HG; Kunitz, A; Lindner, LH; Liu, X; Richter, S; Schöffski, P; Schuler, M; Steffen, B; Stein, A; Zimmermann, S | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Benhadji, KA; Le Cesne, A; Massard, C; Mir, O; Soria, JC; Watson, S | 1 |
| Abe, K; Fujita, M; Hashimoto, Y; Hayashi, M; Kobayashi, Y; Ohira, H; Takahashi, A | 1 |
| Houchi, H; Kawakita, K; Kosaka, S; Kuroda, Y; Okazaki, T; Suzuki, K; Takahashi, K; Tanaka, H; Tatsumichi, T | 1 |
| Asanuma, K; Hagi, T; Nakamura, T; Sudo, A | 1 |
| Fukasawa, N; Nomura, S; Teshima, Y | 1 |
| Abdelhamid, AH; Agarwal, S; Bobbili, PJ; Chugh, R; Demetri, GD; Duh, MS; Gounder, MM; Huynh, L; Lax, AK; Merriam, P; Patel, SR; Rajarethinam, A; Ratan, R; Thornton, M; Totev, TI; Van Tine, BA; Villalobos, VM; Whalen, J; Yang, J | 1 |
| Alameh, IA; Assi, HI; Charafeddine, M; Farhat, F; Halim, NA; Karak, FE; Khoury, J; Nakib, CE; Sayed, RE; Zerdan, MB | 1 |
| Crysandt, M; Cygon, F; Egerer, G; Eigendorff, E; Heißner, K; Kasper, B; Kessler, T; Kopp, HG; Kunitz, A; Lindner, LH; Mayer-Steinacker, R; Meinert, F; Niederwieser, D; Petersen, I; Reichardt, P; Rüssel, J; Schmoll, HJ; Steighardt, J; Stein, A | 1 |
| Bakhshi, S; Biswas, B; Kataria, B; Pushpam, D; Sharma, A | 1 |
| Baek, W; Han, JW; Jeon, MK; Kim, HS; Kim, JH; Kim, SH; Kim, SK; Lee, YH; Woo, HY | 1 |
| Bauer, S; Dieckmann, N; Schildhaus, HU | 1 |
| Abbinanti, S; Agulnik, M; Attia, S; Cehic, R; Charlson, J; Helenowski, I; Hirbe, AC; Milhem, M; Mohindra, N; Monga, V; Okuno, S; Oppelt, P; Robinson, S; Schulte, B; Van Tine, BA | 1 |
| Endo, M; Kanno, N; Nakahashi, K; Numahata, K; Shiikawa, M; Shiono, S | 1 |
| Desar, IME; Kaal, SEJ; Soomers, VLMN; van der Graaf, WTA; van Erp, NP; Verwiel, J | 1 |
| Araki, N; Kawai, A; Takahashi, S; Ueda, T; Yonemori, K | 1 |
| Benson, C; Freivogel, KW; Gelderblom, H; Grignani, G; Jobanputra, M; Judson, IR; Katz, D; Manson, SC; Merimsky, O; Mungul, A; Sanfilippo, R; Stein, D | 1 |
| Deguchi, S; Endo, M; Hayashi, N; Katagiri, H; Mitsuya, K; Murata, H; Nakasu, Y; Takahashi, M; Wasa, J | 1 |
| Abe, S; Akiyama, T; Goto, T; Hirai, T; Ikegami, M; Kawano, H; Kobayashi, H; Ohki, T; Oka, H; Okuma, T; Sato, K; Sawada, R; Shinoda, Y; Tanaka, S | 1 |
| Bupathi, M; Chen, JL; Hays, JL | 1 |
| Benjamin, RS; Dembla, V; Fu, S; Groisberg, R; Herzog, CE; Hess, K; Hong, DS; Janku, F; Karp, DD; Meric-Bernstam, F; Patel, S; Piha-Paul, SA; Ravi, V; Roszik, J; Somaiah, N; Subbiah, V; Wheler, J; Zinner, R | 1 |
| Kim, HJ; Kim, Y; Lee, J; Lee, SJ; Park, SH | 1 |
| Sleijfer, S; Vos, M | 1 |
| Díaz Gómez, E; García Díaz, B; Hidalgo Correas, FJ; Puebla Villaescusa, A; Ramírez Cruz, S; Salcedo Mingoarranz, ÁL | 1 |
| Alavi, SN; Florou, V; Tinoco, G; Trent, JC; Wilky, BA | 1 |
| Baich, TM; Derbala, MH; Guo, AS; Ho, TH; Justice, CN; Kempton, AN; Smith, SA | 1 |
| Anurova, O; Asano, N; Ben-Ami, E; Benjamin, RS; Blay, JY; Boye, K; Brahmi, M; Broto, JM; Brunello, A; Casali, PG; Collini, P; Dei Tos, AP; Desar, IME; Fedenko, A; Flucke, U; Frezza, AM; Gelderblom, H; Grignani, G; Gronchi, A; Hall, KS; Hornick, JL; Jones, RL; Kawai, A; Lo Vullo, S; Lobmaier, I; Lucibello, F; Mariani, L; Mir, O; Palmerini, E; Philippe, T; Picci, P; Ranchere, D; Ratan, R; Renne, SL; Rutkowski, P; Sbaraglia, M; Stacchiotti, S; Teterycz, P; Thway, K; Vincenzi, B; Wagner, AJ; Wagrodzki, M; Wang, WL; Yoshida, A | 1 |
| Chang, YS; Chou, WC; Huang, KG; Huang, PW; Hung, CY; Liau, CT; Liu, CT; Lu, CH; Shen, WC; Su, YL | 1 |
| Aboelhassan, R; Barsoum, M; Basaran, M; Erman, M; Esma, K; Hanene, D; Kamel, B; Karaca, B; Memon, MA; Pilipovic, V; Sevinc, A; Slader, C | 1 |
| Ahmed, T; Balagani, A; Grosu, HB; Muhammad, HA; Ost, DE; Sabath, B; Vakil, E; Vial, MR | 1 |
| Hayashi, K; Igarashi, K; Miwa, S; Takeuchi, A; Tsuchiya, H; Yamamoto, N | 1 |
| Itonaga, I; Iwasaki, T; Kawano, M; Tanaka, K; Tsumura, H | 1 |
| Trent, JC; Van Tine, BA | 1 |
| Blay, JY; Gelderblom, H; Gronchi, A; Le Cesne, A; Leahy, M; Lia, M; Litière, S; Mathijssen, RHJ; Mir, O; Sleijfer, S; Touati, N; Van der Graaf, WT; Van Erp, NP; Young, R | 1 |
| Gourd, E | 1 |
| DE Geus-Oei, LF; Desar, IME; Grootjans, W; Koenen, AM; Oyen, WJ; Steeghs, N; VAN DER Graaf, WT; VAN Erp, NP; Verheijen, RB; Vlenterie, M | 1 |
| Attenberger, U; Derigs, HG; Dimitrakopoulou-Strauss, A; Gaiser, T; Hohenberger, P; Jakob, J; Karampinis, I; Kasper, B; Nowak, K; Pilz, L; Ronellenfitsch, U; Sachpekidis, C; Schwarzbach, M | 1 |
| Hohenberger, P; Ronellenfitsch, U | 1 |
| Von Mehren, M | 1 |
| Chen, JL; Hoffman, SE; Legasto, CS; McLaughlin, EM; Pisano, SG; Porter, K | 1 |
| Araki, N | 1 |
| Sleijfer, S; Verweij, J | 1 |
| Meyer, CF; Trent, JC; Wilky, BA | 1 |
| Ahern, CH; Baruchel, S; Blaney, SM; Glade Bender, JL; Harris, P; Ingle, AM; Lee, A; Reid, JM; Roberts, T; Voss, SD; Weigel, BJ; Wu, B | 1 |
| Manson, SC; Penel, N; Powell, S; Sharma, S; Takyar, S | 1 |
| Ammendola, M; Citraro, R; De Sarro, G; Donato Di Paola, E; Gadaleta, CD; Gallelli, L; Mammì, M; Marech, I; Ranieri, G; Russo, E | 1 |
| Chow, WA; Eroglu, Z; Kim, J; Wilczynski, S | 1 |
| Bauer, S; Hodge, RA; Kasper, B; Kerst, JM; Litière, S; Marreaud, S; Sleijfer, S; van der Graaf, WTA; Verweij, J | 1 |
| Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Tavallai, S | 1 |
| Ae, K; Gokita, T; Inagaki, L; Matsumoto, S; Motoi, N; Nakano, K; Shimoji, T; Takahashi, S; Tanizawa, T; Tomomatsu, J | 2 |
| Ferrari, S; Paioli, A; Palmerini, E | 1 |
| Cornillie, J; Hompes, D; Li, H; Schöffski, P; Wozniak, A | 1 |
| Bay, JO; Brotelle, T | 1 |
| Cuesta, M; Guix, M; Hernández-Pastor, LJ; Lavernia, J; Villa, G | 1 |
| Ames, E; Borys, D; Canter, RJ; Chen, M; Grossenbacher, SK; Li, CS; Mac, S; Monjazeb, AM; Murphy, WJ; Sayers, TJ; Smith, RC; Tellez, J | 1 |
| Ahmed, M; Coleman, CN; Curran, WJ; Dicker, AP; Finkelstein, SE; Houghton, P; Kirsch, DG; Machtay, M; Monjazeb, AM; Teicher, BA; Vikram, B; Wang, D; Wong, P; Xu-Welliver, M | 1 |
| Kawai, A; Kawashima, M; Kobayashi, E; Kobayashi, K; Koyama, T; Setsu, N | 1 |
| Chryssidis, S; Cohen, L; Kotasek, D; Neuhaus, S | 1 |
| Cho, YJ; Kim, HS; Kim, SH; Kim, SJ; La Choi, Y; Lee, J; Lee, SJ; Park, SH; Rha, SY; Shin, KH; Yoo, KH | 1 |
| Borst, G; de Pree, I; Dewit, L; Gelderblom, H; Haas, RL; Hartgrink, HH; Kerst, JM; Nout, RA; Scholten, A; Sleijfer, S; Steeghs, N; van Boven, HH; van Coevorden, F; van der Hage, J; Verhoef, C | 1 |
| Flaherty, C; Holland, J | 1 |
| Blay, JY; Bottomley, A; Chawla, SP; Coens, C; Hodge, RA; Judson, I; Litière, S; Lugowska, I; Manson, SC; Marreaud, S; Prins, JB; Sanfilippo, R; van der Graaf, WT | 1 |
| Komarov, YI; Latipova, DH; Novik, AV; Protsenko, SA; Semenova, AI; Teletaeva, GM | 1 |
| Bouvet, M; Chishima, T; Endo, I; Hiroshima, Y; Hoffman, RM; Ichikawa, Y; Maawy, A; Matsuyama, R; Mii, S; Miwa, S; Momiyama, M; Mori, R; Murakami, T; Tanaka, K; Uehara, F; Yamamoto, M; Yano, S; Zhang, N; Zhang, Y; Zhao, M | 1 |
| Kato, S | 1 |
| Agulnik, M; Mohindra, N | 1 |
| Chawla, SP; Dewji, R; Duffaud, F; Judson, I; Le Cesne, A; Litière, S; Marreaud, S; Papai, Z; Ray-Coquard, I; Schöffski, P; Sleijfer, S; van der Graaf, WT; Verweij, J | 1 |
| Agulnik, M; Carvajal, RD; Chi, P; Chmielowski, B; Crago, AM; D'Angelo, SP; Dickson, MA; Ezeoke, MO; Gounder, MM; Hameed, M; Healey, JH; Keohan, ML; Landa, J; Luke, JJ; Munhoz, RR; Qin, LX; Schwartz, GK; Singer, S; Singh, AS; Tap, WD; Van Tine, BA | 1 |
| Chen, JL; Koehler, K; Liebner, D | 1 |
| Berendes, BJ; Everaert, H; Lefesvre, P; Schallier, D | 1 |
| Attenberger, U; Derigs, HG; Dimitrakopoulou-Strauss, A; Egerer, G; Fröhling, S; Gaiser, T; Hohenberger, P; Jakob, J; Kasper, B; Nowak, K; Pilz, LR; Ronellenfitsch, U; Schwarzbach, M | 1 |
| Araki, N; Esaki, T; Fukasawa, N; Hiraga, H; Ishii, T; Kawai, A; Machida, M; Matsumine, A; Ozaki, T; Sugiura, H; Ueda, T | 1 |
| Araki, N; Boku, S; Goto, T; Hiraga, H; Honoki, K; Kawai, A; Matsumine, A; Nakamura, T; Nishida, Y; Sudo, A; Sugiura, H; Ueda, T; Yasuda, T; Yonemoto, T | 1 |
| Benson, C; Blay, JY; Chawla, S; Dewji, MR; Gil, T; Judson, I; Le Cesne, A; Litière, S; Marréaud, S; Papai, Z; Piperno-Neumann, S; Ray-Coquard, I; Schöffski, P; Sleijfer, S; van der Graaf, WTA | 1 |
| Becze, E | 1 |
| Doi, T; Nishida, T | 1 |
| Cui, PF; Jiang, HL; Qiao, JB; Wang, FZ; Xing, L; Xu, CX; Zhang, BF; Zhang, JL | 1 |
| Carbini, M; Maki, RG; Pang, A | 1 |
| Azvolinsky, A | 1 |
| Abe, K; Hayashi, K; Higuchi, T; Inatani, H; Miwa, S; Takeuchi, A; Taniguchi, Y; Tsuchiya, H; Yamamoto, N | 1 |
| Grünwald, V; Karch, A; Koch, A | 1 |
| Azraq, Y; Eleyan, F; Gill, S; Katz, D; Merimsky, O; Peretz, T | 1 |
| Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Goldwasser, F; Huillard, O; Jouinot, A; Thomas-Schoemann, A; Tlemsani, C; Vidal, M | 1 |
| Agrafiotis, AC; Grosdidier, G; Prieto, M; Rios, M; Siat, J; Verhaeghe, JL | 1 |
| Kaneko, T; Koike, K; Kurata, T; Motobayashi, M; Nakazawa, Y; Sano, K; Shigemura, T; Sumi, T; Suzuki, S; Watanabe, T | 1 |
| Blay, JY; Clippe, S; Collard, O; Ducimetiere, F; Ladarre, N; Laramas, M; Manson, S; Mercier, F; Ray-Coquard, I; Stefani, L; Suchaud, JP; Tehard, B | 1 |
| Blay, JY; Collin, F; De Brauwer, A; Le Cesne, A; Marreaud, S; Pandite, L; Papai, Z; Ray-Coquard, I; Schöffski, P; Scurr, M; Sleijfer, S; van Glabbeke, M; Verweij, J | 1 |
| Deville, JL; Duffaud, F; Huynh, T; Salas, S | 1 |
| Hohenberger, P; Kasper, B | 1 |
| Bramwell, VH | 1 |
| Aglietta, M; Araki, N; Beppu, Y; Blay, JY; Bui-Nguyen, B; Casali, PG; Chawla, SP; Coens, C; Dei Tos, AP; Demetri, GD; Dewji, MR; Fletcher, CD; Gelderblom, H; Hodge, R; Hohenberger, P; Judson, IR; Kim, DW; Le Cesne, A; Marreaud, S; Ouali, M; Schöffski, P; Staddon, AP; van der Graaf, WT | 1 |
| Schöffski, P | 1 |
| Ray-Coquard, I; Thomas, D | 1 |
| Blay, JY; Burger, H; Collin, F; Gorlia, T; Hohenberger, P; Lamers, C; Le Cesne, A; Marreaud, S; Pandite, L; Scurr, M; Sleijfer, S | 1 |
| Issels, RD; Lindner, LH | 1 |
| Deeks, ED | 1 |
| Chmielowski, B; Federman, N; Tap, WD | 1 |
| Dittmann, K; Fulda, S; Graab, U; Hahn, H; Marklein, D; Naumann, I; Nitzki, F; Ridzewski, R; Rosenberger, A; Wienands, J; Wojnowski, L; Yan, T | 1 |
| Arai, H; Fukasawa, N; Ueta, F | 1 |
29 review(s) available for indazoles and Sarcoma
| Article | Year |
|---|---|
Pazopanib-induced fatal heart failure in a patient with unresectable soft tissue sarcoma and review of literature.
Topics: Doxorubicin; Dyspnea; Female; Heart Failure; Humans; Indazoles; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Stroke Volume; Sulfonamides; Ventricular Function, Left | 2020 |
The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.
Topics: Drug Resistance, Neoplasm; Humans; Indazoles; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma; Sulfonamides | 2019 |
Tropomyosin receptor kinase inhibitors in the management of sarcomas.
Topics: Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Indazoles; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Receptor, trkC; Sarcoma | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Tropomyosin receptor kinases in sarcomas - of joy and despair.
Topics: Benzamides; Humans; Indazoles; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Sarcoma | 2021 |
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Furans; Humans; Indazoles; Japan; Ketones; Pyrimidines; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin | 2017 |
Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.
Topics: Brain; Fatal Outcome; Female; Humans; Indazoles; Magnetic Resonance Imaging; Middle Aged; Posterior Leukoencephalopathy Syndrome; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Sulfonamides | 2018 |
EJC's biennial report on metastatic soft tissue sarcoma: State of the art and future perspectives.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Therapy; Forecasting; Humans; Indazoles; Neoplasm Metastasis; Pyrimidines; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin | 2018 |
A precision medicine approach in sarcoma: identification of patients who may benefit from early use of pazopanib.
Topics: Humans; Indazoles; Precision Medicine; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2018 |
The Impact of Pazopanib on the Cardiovascular System.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cardiovascular Diseases; Cardiovascular System; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Risk Assessment; Risk Factors; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Treatment Outcome | 2018 |
Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Drug Therapy; Furans; Humans; Immunotherapy, Adoptive; Indazoles; Ipilimumab; Ketones; Nivolumab; Osteosarcoma; Progression-Free Survival; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Trabectedin | 2019 |
Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Doxorubicin; Female; Humans; Indazoles; Male; Neoplasm Metastasis; Neoplasm Staging; Odds Ratio; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides; Treatment Outcome | 2019 |
Pazopanib, a new therapy for metastatic soft tissue sarcoma.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Disease-Free Survival; Humans; Indazoles; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sulfonamides | 2013 |
Pazopanib in sarcomas: expanding the PALETTE.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indazoles; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides | 2013 |
Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review.
Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Gemcitabine; Humans; Indazoles; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Treatment Failure | 2013 |
Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma.
Topics: Angiogenesis Inhibitors; Animals; Humans; Indazoles; Molecular Targeted Therapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Signal Transduction; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Emerging therapeutic targets for synovial sarcoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bevacizumab; Everolimus; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sarcoma, Synovial; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases | 2014 |
Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease.
Topics: Antineoplastic Agents; Dioxoles; Doxorubicin; Evidence-Based Medicine; Humans; Ifosfamide; Indazoles; Pyrimidines; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2014 |
[Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sarcoma; Sulfonamides | 2014 |
Combining targeted agents with modern radiotherapy in soft tissue sarcomas.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Cycle; Cell Survival; Chemotherapy, Adjuvant; Cyclin-Dependent Kinase 4; Humans; Indazoles; Indoles; Ipilimumab; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Pyrroles; Radiotherapy, Adjuvant; Sarcoma; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment | 2014 |
[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Denosumab; Drug Discovery; Everolimus; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sarcoma; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Drug Design; Humans; Indazoles; Molecular Targeted Therapy; Pyrimidines; Sarcoma; Sulfonamides | 2015 |
Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults: A Review.
Topics: Adult; Antineoplastic Agents; Dioxoles; Furans; Humans; Indazoles; Ketones; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment | 2016 |
Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
Topics: Aged; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Interactions; Drug Monitoring; Humans; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrimidines; Sarcoma; Sulfonamides | 2016 |
[Antiangionic drugs in soft tissue sarcoma].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Doxorubicin; Humans; Indazoles; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Pazopanib in the treatment of soft tissue sarcoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Humans; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides | 2012 |
[Soft-tissue sarcoma: recent developments].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Gemcitabine; Humans; Hyperthermia, Induced; Indazoles; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sirolimus; Soft Tissue Neoplasms; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Drug Substitution; Drugs, Investigational; Endpoint Determination; Humans; Indazoles; Molecular Targeted Therapy; Neoplasm Metastasis; Outcome and Process Assessment, Health Care; Prognosis; Pyrimidines; Sarcoma; Sirolimus; Sulfonamides; Survival Rate; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
[Pharmacological profile and clinical results in advanced soft tissue sarcoma patients of pazopanib hydrochloride (Votrient(®))].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Indazoles; Mice; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Treatment Outcome | 2013 |
25 trial(s) available for indazoles and Sarcoma
| Article | Year |
|---|---|
A phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma.
Topics: Humans; Indazoles; Neoadjuvant Therapy; Prospective Studies; Pyrimidines; Sarcoma; Sulfonamides | 2021 |
A post hoc analysis of the EPAZ trial: The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome.
Topics: Activities of Daily Living; Aged; Doxorubicin; Humans; Indazoles; Sarcoma; Soft Tissue Neoplasms | 2023 |
A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chest Pain; Cross-Over Studies; Diarrhea; Disease Progression; Double-Blind Method; Female; Humans; Indazoles; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Treatment Outcome | 2020 |
Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome; Young Adult | 2020 |
A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy.
Topics: Aged; Female; Humans; Indazoles; Male; Neoplasm Metastasis; Progression-Free Survival; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2020 |
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study.
Topics: Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Chemotherapy-Induced Febrile Neutropenia; Doxorubicin; Drug Administration Schedule; Female; Humans; Indazoles; Male; Middle Aged; Neutropenia; Patient Reported Outcome Measures; Progression-Free Survival; Pyrimidines; Quality of Life; Sarcoma; Sulfonamides | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Indazoles; Middle Aged; Pyrimidines; Quality of Life; Sarcoma; Sulfonamides; Treatment Outcome; Young Adult | 2021 |
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Osteosarcoma; Prospective Studies; Pyrimidines; Sarcoma; Sulfonamides; Topotecan; Treatment Outcome; Young Adult | 2021 |
Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Gastric Acid; Humans; Indazoles; Male; Middle Aged; Neoplasm Grading; Prognosis; Pyrimidines; Sarcoma; Sulfonamides; Survival Analysis; Treatment Outcome | 2019 |
GAS agents limit pazopanib activity in soft-tissue sarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Indazoles; Male; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Sarcoma; Sulfonamides | 2019 |
Preoperative Pazopanib in High-Risk Soft Tissue Sarcoma: Phase II Window-of Opportunity Study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04).
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Follow-Up Studies; Germany; Humans; Indazoles; Male; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Prognosis; Pyrimidines; Risk Factors; Sarcoma; Sulfonamides | 2019 |
Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Indazoles; Male; Neoplasms; Pyrimidines; Sarcoma; Sulfonamides; Young Adult | 2013 |
Pazopanib and soft-tissue sarcomas. Too toxic.
Topics: Angiogenesis Inhibitors; Double-Blind Method; Heart Failure; Humans; Indazoles; Liver; Pneumothorax; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Sarcoma; Sulfonamides | 2013 |
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
Topics: Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Placebos; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sarcoma; Sulfonamides; Treatment Outcome | 2014 |
A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.
Topics: Adult; Aged; Angiogenesis Inhibitors; Chemoradiotherapy, Adjuvant; Extremities; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Young Adult | 2015 |
Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for res
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Pyrimidines; Quality of Life; Sarcoma; Sulfonamides; Treatment Outcome; Young Adult | 2015 |
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoadjuvant Therapy; Pyrimidines; Sarcoma; Sulfonamides; Taxoids; Treatment Outcome | 2015 |
Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS).
Topics: Angiogenesis Inhibitors; Chemotherapy, Adjuvant; Disease-Free Survival; Endothelial Progenitor Cells; Germany; Humans; Indazoles; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Risk; Sarcoma; Sulfonamides | 2016 |
A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup.
Topics: Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Double-Blind Method; Female; Humans; Indazoles; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Indazoles; Leiomyosarcoma; Middle Aged; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Survival Rate; Uterine Neoplasms; Young Adult | 2016 |
A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial.
Topics: Age Factors; Aged; Antibiotics, Antineoplastic; Belgium; Clinical Protocols; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Geriatric Assessment; Germany; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Research Design; Risk Factors; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Time Factors; Treatment Outcome | 2016 |
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 620
Topics: Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2009 |
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Treatment Outcome; Young Adult | 2012 |
Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Cytokines; Disease-Free Survival; Female; Humans; Indazoles; Interleukin-12 Subunit p40; Male; Membrane Proteins; Middle Aged; Placenta Growth Factor; Polycomb-Group Proteins; Pregnancy Proteins; Pyrimidines; Repressor Proteins; Sarcoma; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2012 |
73 other study(ies) available for indazoles and Sarcoma
| Article | Year |
|---|---|
Prognostic Importance of Inflammatory Indexes in Patients Treated by Pazopanib for Soft Tissue Sarcoma.
Topics: Humans; Indazoles; Lymphocytes; Neutrophils; Prognosis; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides | 2022 |
Gene expression-based prediction of pazopanib efficacy in sarcoma.
Topics: Gene Expression; Humans; Indazoles; Prospective Studies; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Young Adult | 2022 |
Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response.
Topics: Humans; Indazoles; Pyrimidines; Sarcoma; Sulfonamides | 2023 |
Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; East Asian People; Humans; Indazoles; Kidney Neoplasms; Sarcoma; Soft Tissue Neoplasms | 2023 |
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study.
Topics: Adult; Female; Humans; Indazoles; Leiomyosarcoma; Male; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Turkey | 2023 |
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Sarcoma; Sulfonamides; Survival Analysis; Treatment Outcome | 2019 |
CT-morphologic and CT-textural patterns of response in inoperable soft tissue sarcomas treated with pazopanib-a preliminary retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Deoxycytidine; Female; Gemcitabine; Heart Neoplasms; Humans; Indazoles; Male; Middle Aged; Prognosis; Progression-Free Survival; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome; Tunica Intima | 2020 |
Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Giant Cell Tumor of Tendon Sheath; Humans; Imatinib Mesylate; Indazoles; Pyrimidines; Radiotherapy, Adjuvant; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2020 |
The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Young Adult | 2020 |
Possibility for Dose Optimization of Pazopanib from Its Plasma Concentration in Japanese Patients with Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Asian People; Carcinoma, Renal Cell; Drug Monitoring; Female; Humans; Indazoles; Japan; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome; Young Adult | 2020 |
Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study.
Topics: Adult; Female; Humans; Indazoles; Leiomyosarcoma; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Survival Analysis | 2021 |
Vastus lateralis myocutaneous flap for ischial skin wound following the treatment of epithelioid sarcoma using pazopanib.
Topics: Adult; Angiogenesis Inhibitors; Buttocks; Combined Modality Therapy; Female; Humans; Indazoles; Magnetic Resonance Imaging; Myocutaneous Flap; Pyrimidines; Quadriceps Muscle; Sarcoma; Sulfonamides; Treatment Outcome; Wound Healing | 2020 |
Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers; Exome Sequencing; Female; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Sarcoma; Sulfonamides | 2020 |
CORR Insights®: Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
Topics: Biomarkers; Humans; Indazoles; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2020 |
Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
Topics: Angiogenesis Inhibitors; Cohort Studies; Female; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Republic of Korea; Retrospective Studies; Sarcoma; Sulfonamides; Survival Analysis | 2020 |
Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft tissue sarcoma patients.
Topics: Benzazepines; Humans; Indazoles; Pyrimidines; Sarcoma; Sulfonamides | 2020 |
Pazopanib-induced mixed liver injury in a patient with soft-tissue sarcoma, but without the UGT1A1*28 mutation: a case report.
Topics: Aged; Humans; Indazoles; Liver; Male; Mutation; Pyrimidines; Sarcoma; Sulfonamides | 2021 |
Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib.
Topics: Angiogenesis Inhibitors; Diagnosis, Differential; Female; Humans; Indazoles; Magnetic Resonance Imaging; Middle Aged; Posterior Leukoencephalopathy Syndrome; Pyrimidines; Sarcoma; Sulfonamides; Uterine Neoplasms | 2021 |
Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Female; Furans; Humans; Indazoles; Japan; Kaplan-Meier Estimate; Ketones; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrimidines; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Survival Analysis; Trabectedin; Treatment Outcome | 2020 |
Postmarketing observational study of pazopanib in patients with metastatic soft tissue sarcoma in Japan.
Topics: Adolescent; Adult; Aged; Female; Humans; Incidence; Indazoles; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Progression-Free Survival; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Treatment Outcome; Young Adult | 2021 |
Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytidine; Female; Gemcitabine; Health Records, Personal; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Treatment Outcome; United States; Young Adult | 2021 |
Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
Topics: Adult; Aged; Appetite; Fatigue; Female; Humans; Indazoles; Lebanon; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Tertiary Care Centers; Young Adult | 2021 |
Oral metronomic chemotherapy is a cost effective alternative to pazopanib in advanced soft tissue sarcoma.
Topics: Cost-Benefit Analysis; Humans; Indazoles; Pyrimidines; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2022 |
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; B7-H1 Antigen; Female; Humans; Indazoles; Male; Middle Aged; Prognosis; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides | 2021 |
[Pneumothorax during Pazopanib Therapy in a Patient with Soft Tissue Sarcoma].
Topics: Aged; Humans; Indazoles; Kidney Neoplasms; Male; Pneumothorax; Pyrimidines; Sarcoma; Sulfonamides | 2021 |
Fatal heart failure in a young adult female sarcoma patient treated with pazopanib.
Topics: Adult; Chemical and Drug Induced Liver Injury; Fatal Outcome; Female; Heart Failure; Humans; Indazoles; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2017 |
Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study
Topics: Angiogenesis Inhibitors; Compassionate Use Trials; Disease-Free Survival; Female; Hemangiosarcoma; Humans; Indazoles; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Pyrimidines; Retrospective Studies; Sarcoma; Sarcoma, Synovial; Solitary Fibrous Tumors; Sulfonamides; Survival Rate; Time Factors; Uterine Neoplasms | 2017 |
Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Blood Platelets; Cell Count; Disease-Free Survival; Female; Humans; Indazoles; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Proportional Hazards Models; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome; Young Adult | 2018 |
Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Disease Progression; Female; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Temozolomide; Treatment Failure; Vascular Endothelial Growth Factor A; Young Adult | 2017 |
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Histone Deacetylase Inhibitors; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Receptor, ErbB-2; Sarcoma; Signal Transduction; Sulfonamides; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2017 |
Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Salvage Therapy; Sarcoma; Sulfonamides; Survival Analysis; Uterine Neoplasms | 2018 |
[Atrial flutter probably related to pazopanib: A case report].
Topics: Angiogenesis Inhibitors; Atrial Flutter; Carcinoma, Renal Cell; Electrocardiography; Fatal Outcome; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Sarcoma; Sulfonamides | 2018 |
Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Pyrimidines; Remission Induction; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sarcoma; Sulfonamides; Young Adult | 2018 |
Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population.
Topics: Adult; Aged; Asian People; Disease Progression; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Indazoles; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Taiwan; Treatment Outcome | 2018 |
Middle East observational study in metastatic soft tissue sarcoma: an epidemiological study on the treatment patterns (MOON).
Topics: Adult; Africa, Northern; Aged; Aged, 80 and over; Drug Therapy; Female; Humans; Indazoles; Male; Middle Aged; Middle East; Neoplasm Metastasis; Pyrimidines; Radiotherapy; Retrospective Studies; Sarcoma; Sulfonamides; Surgical Procedures, Operative | 2018 |
Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study.
Topics: Adult; Aged; Case-Control Studies; Female; Humans; Indazoles; Logistic Models; Lung Neoplasms; Male; Middle Aged; Pneumothorax; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Factors; Sarcoma; Sulfonamides | 2018 |
How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
Topics: Deoxycytidine; Gemcitabine; Humans; Indazoles; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2019 |
Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Indazoles; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome | 2019 |
ASO Author Reflections: Preoperative Pazopanib for High-Risk Soft Tissue Sarcoma: Better Patient Selection is Needed.
Topics: Humans; Indazoles; Patient Selection; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2019 |
Honing in on Subtypes to Guide More Individualized Treatment of Soft Tissue Sarcoma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Gastric Acid; Humans; Indazoles; Molecular Targeted Therapy; Precision Medicine; Pyrimidines; Sarcoma; Sulfonamides | 2019 |
Effect of Acid-Suppressive Strategies on Pazopanib Efficacy in Patients With Soft-Tissue Sarcoma.
Topics: Aged; Female; Humans; Hypertension; Indazoles; Male; Middle Aged; Progression-Free Survival; Proton Pump Inhibitors; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome | 2019 |
Fusion gene-oriented precision medicine in soft tissue sarcoma.
Topics: Chondrosarcoma; Humans; Indazoles; Precision Medicine; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2019 |
Complete pathologic response in soft tissue sarcoma lung metastases with pazopanib.
Topics: Angiogenesis Inhibitors; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Pyrimidines; Sarcoma; Sulfonamides; Tomography, X-Ray Computed | 2014 |
Pazopanib and HDAC inhibitors interact to kill sarcoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Cell Line, Tumor; Drug Synergism; Female; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Indazoles; Membrane Proteins; Mice, Nude; Microtubule-Associated Proteins; Pyrimidines; Receptors, Death Domain; Sarcoma; Signal Transduction; Sulfonamides; Valproic Acid | 2014 |
Incidence of pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment.
Topics: Adult; Angiogenesis Inhibitors; Humans; Incidence; Indazoles; Male; Middle Aged; Pneumothorax; Pyrimidines; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2014 |
Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dioxoles; Disease Progression; Drug Costs; Humans; Indazoles; Probability; Pyrimidines; Quality-Adjusted Life Years; Sarcoma; Spain; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2015 |
Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.
Topics: Aldehyde Dehydrogenase 1 Family; Angiogenesis Inhibitors; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Indazoles; Isoenzymes; Liver Neoplasms; Lung Neoplasms; Mice, Inbred NOD; Neoadjuvant Therapy; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Retinal Dehydrogenase; Sarcoma; Sorafenib; Sulfonamides; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2014 |
Reversible hair depigmentation in a Japanese female treated with pazopanib.
Topics: Adult; Bone Neoplasms; Female; Hair Diseases; Hip Joint; Humans; Indazoles; Pigmentation Disorders; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma; Sulfonamides | 2014 |
Bronchopleural fistula arising after commencement of pazopanib for progressive sarcoma.
Topics: Angiogenesis Inhibitors; Bronchial Fistula; Female; Humans; Indazoles; Lung Neoplasms; Middle Aged; Pleural Diseases; Pyrimidines; Sarcoma; Sulfonamides | 2017 |
Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indazoles; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Patient Selection; Prognosis; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Treatment Outcome | 2015 |
Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.
Topics: Adult; Aged; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides | 2015 |
Nursing considerations for patients with sarcoma on pazopanib therapy.
Topics: Angiogenesis Inhibitors; Clinical Competence; Humans; Indazoles; New York; Patient Education as Topic; Practice Patterns, Nurses'; Pyrimidines; Sarcoma; Sulfonamides; Surveys and Questionnaires | 2015 |
[Systemic therapy of soft tissue sarcomas].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ifosfamide; Indazoles; Indoles; Male; Molecular Targeted Therapy; Neoadjuvant Therapy; Niacinamide; Palliative Care; Phenylurea Compounds; Polyethylene Glycols; Pyrimidines; Pyrroles; Radiography; Sarcoma; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2015 |
Tumor-Targeting Salmonella typhimurium A1-R Arrests a Chemo-Resistant Patient Soft-Tissue Sarcoma in Nude Mice.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Disease Models, Animal; Gemcitabine; Indazoles; Mice; Mice, Nude; Pyrimidines; Salmonella Infections; Salmonella typhimurium; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trial
Topics: Adult; Aged; Blood Pressure; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Europe; Female; Follow-Up Studies; Humans; Hypertension; Indazoles; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Sarcoma; Sulfonamides | 2015 |
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
Topics: Angiogenesis Inhibitors; Base Sequence; Disease-Free Survival; Female; Genetic Markers; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Retinoblastoma Protein; Retrospective Studies; Sarcoma; Sequence Analysis, DNA; Sulfonamides; Treatment Outcome; Tumor Suppressor Protein p53 | 2016 |
Effective Treatment of Pleural Epitheloid Hemangio-endothelioma with Pazopanib: A Case Report.
Topics: Adult; Disease-Free Survival; Hemangioendothelioma; Humans; Indazoles; Male; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome | 2016 |
The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chemical and Drug Induced Liver Injury; Disease-Free Survival; Female; Fibrosarcoma; Humans; Hypertension; Indazoles; Japan; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Neoplasm Recurrence, Local; Neurilemmoma; Pneumothorax; Product Surveillance, Postmarketing; Pyrimidines; Retrospective Studies; Sarcoma; Sarcoma, Synovial; Sulfonamides; Survival Analysis; Thrombocytopenia | 2016 |
Patient Education Needs With Pazopanib Therapy for Soft Tissue Sarcoma.
Topics: Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Indazoles; Nurse's Role; Patient Education as Topic; Pyrimidines; Sarcoma; Sulfonamides | 2016 |
Pazopanib for both GIST and soft-tissue sarcoma.
Topics: Humans; Indazoles; Pyrimidines; Sarcoma; Sulfonamides | 2016 |
In vivo synergistic antitumor effect and safety of siRNA and lonidamine dual-loaded hierarchical targeted nanoparticles.
Topics: Animals; Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; In Situ Nick-End Labeling; Indazoles; Male; Mice; Mice, Inbred ICR; Nanoparticles; Polymers; RNA, Small Interfering; Sarcoma; Xenograft Model Antitumor Assays | 2016 |
Heterogeneous and Rare: Toward Histology-Specific Treatment of Soft-Tissue Sarcoma.
Topics: Antineoplastic Agents; Chromosomal Proteins, Non-Histone; Dioxoles; Disease-Free Survival; DNA-Binding Proteins; Furans; Humans; Indazoles; Ketones; Molecular Targeted Therapy; Mutation; Pyrimidines; Sarcoma; SMARCB1 Protein; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Transcription Factors | 2016 |
Balancing Prolonged Survival with QoL Using Low-dose Pazopanib Maintenance: A Comparison with the PALETTE Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Histiocytoma, Malignant Fibrous; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Quality of Life; Retrospective Studies; Sarcoma; Sulfonamides | 2016 |
Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chondrosarcoma; Disease Progression; Drug Administration Schedule; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Sarcoma; Sirolimus; Sulfonamides; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
[Treatment of bilateral spontaneous pneumothorax during pazopanib therapy for pulmonary soft tissue sarcoma metastases. What to do when there is so few evidence?]
Topics: Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Muscle Neoplasms; Pneumonectomy; Pneumothorax; Pyrimidines; Sarcoma; Sulfonamides | 2016 |
Dramatic Reduction in Tumor Size During 5 Months of Pazopanib Therapy in Combination With Ifosfamide, Carboplatin, and Etoposide in an Early Infant With Progressive Soft Tissue Sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Indazoles; Infant; Male; Pyrimidines; Remission Induction; Sarcoma; Sulfonamides | 2017 |
Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS).
Topics: Aged; Antineoplastic Agents; Female; France; Humans; Indazoles; Male; Middle Aged; Prospective Studies; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome | 2017 |
Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.
Topics: Antineoplastic Agents; Humans; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Sulfonamides | 2011 |
Pazopanib and the treatment palette for soft-tissue sarcoma.
Topics: Antineoplastic Agents; Female; Humans; Indazoles; Male; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2012 |
Targeted therapies: pazopanib for soft-tissue sarcoma: a PALETTE of data emerges.
Topics: Clinical Trials, Phase III as Topic; Humans; Indazoles; Molecular Targeted Therapy; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides; Survival Rate | 2012 |
Pazopanib: in advanced soft tissue sarcoma.
Topics: Adult; Angiogenesis Inhibitors; Humans; Indazoles; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides; Treatment Outcome | 2012 |
PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cytochromes c; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Furans; Gene Expression; Humans; Indazoles; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyridines; Pyrimidines; Sarcoma; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |